Prevest Denpro share price today

Prevest Denpro Ltd's share price was ₹376.35 at the close on 30 October 2026. It has been falling for 15 weeks. That is 8.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹359 and ₹510, and at that close it sat 12% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Prevest Denpro Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 6 weeks in a row.

Over the last 5.1 years the share price moved +100% while the NIFTY 500 moved +45%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

For October to December 2025 (the quarter ended 31 December 2025), Prevest Denpro reported revenue of ₹18.4 crore, up 23.0% from ₹14.9 crore a year earlier, and a profit of ₹5.15 crore, up 15.5% from ₹4.46 crore.

Prevest Denpro results: October to December 2025 against a year earlier

The next results, for January to March 2026, were due by 30 May 2026: listed companies must publish quarterly results within 60 days of the quarter's end (the January to March quarter comes with the full-year accounts). This page shows them once our weekly data update has read them.

From the company's reported quarterly results (quarter ended 31 December 2025). Revenue and profit in ₹ crore.

Prevest Denpro closed at ₹376.35 on 30 October 2026, down 28.2% from ₹524.45 a year earlier (31 October 2025) and up 54.9% over five years. Its highest weekly close since October 2021 was ₹668.80 on 12 July 2024.

Prevest Denpro share price: then and now

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

266 weekly closes from 1 October 2021 to 30 October 2026.

30 Oct 2026: Prevest Denpro closed at ₹376.35, down 0.3% on the week and down 0.2% on the month. Results for October to December 2025: Revenue up 23.0% and profit up 15.5% on a year earlier.

The NSE corporate-actions record has no dividend for Prevest Denpro since its first NSE close in our records (1 October 2021), so this page cannot show amounts per share.

Yes. Prevest Denpro Ltd paid out 7% of its profit as dividends in FY25, and it paid a dividend in 3 of its last 7 reported years.

From the NSE corporate-actions record, read 5 November 2026.

Prevest Denpro is not on any of our India lists this week.

Prevest Denpro Ltd earned ₹5.2 Cr of net profit in the Dec 2025 quarter, +15.5% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY25 profit was ₹18.0 Cr. Over 6 years profit has grown 34.8% a year on average. That is 28.0% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹4.5 Cr.

For the full year, FY25 profit was ₹18.0 Cr (+12.5% on the year before).

Why profit moved: revenue changed +23.0% on a year earlier and the margin moved −0.6 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +17.5% and revenue +17.4%. Profit and revenue are moving at about the same pace.

Prevest Denpro Ltd reported ₹18.4 Cr of revenue in the Dec 2025 quarter, +23.0% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 6 years it has grown 22.1% a year on average. The last full year, FY25, came in at ₹63.0 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹71.3 Cr.

FY25 revenue was ₹63.0 Cr, +12.5% on the year before.

Recent pace: the last four quarters grew +17.4% on average, against 22.1% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +17.3%, against +14.9% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +17.0%, against +11.5% a year (accelerating).

Prevest Denpro Ltd's operating margin was 33.9% in the Dec 2025 quarter, 0.6 percentage points lower than the same quarter a year ago. Across 7 years it has been between 20.0% and 40.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −0.6 percentage points on the year while gross margin changed +1.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 72% of Prevest Denpro Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in ₹15.0 Cr of operating cash against ₹18.0 Cr of profit. After ₹2.0 Cr of spending on assets, ₹13.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 72% of profit came in as cash: the cash cycle got 189 days longer between FY20 and FY25, so more of each rupee of profit waits in the business before it arrives.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 189 days longer. The next section looks at where the cash is stuck.

Prevest Denpro Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 211 days in FY25, up from 22 days in FY20. It spent ₹19.0 Cr on assets over the last 3 years. Customers take 45 days to pay, and stock sits for 208 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY25 sales of ₹63.0 Cr, each day of that cycle ties up about ₹0.2 Cr, so roughly ₹36.0 Cr is tied up in the business at any time.

FY25: customers took 45 days to pay and stock sat for 208 days, about 6.8 months of sales sitting as stock, for a full cycle of 211 days, longer than FY20's 22.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 208 days. Customers pay about 45 days after that. Suppliers are paid at 42 days. Together that makes the 211-day cycle.

Spending on assets: ₹19.0 Cr over the last 3 years, against ₹4.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY25): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Prevest Denpro Ltd's P/E is 24.8×, near the low end of its own history: it has been lower only 15% of the time. Its usual P/E (the middle reading) is 32.5×, over 4.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +12.9% while the price moved −28.2%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved −4.9% a year; about +16.4% a year came from earnings growth and about −21.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Prevest Denpro Ltd's business is getting better. Profit growth hit its low 6 quarters ago at −8.8% and has recovered to +15.5% (from single-quarter figures), with ROCE falling at 25.0%. This is based on 9 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: a lasting rise from a low is what this page is built to show.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Prevest Denpro Ltd earned a ROCE of 25% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 28.6% net margin and 0.56× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY25): a 28.6% net margin × 0.56× asset turnover × 1.07× leverage (assets divided by equity) ≈ 17.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

Prevest Denpro Ltd had ₹0.0 Cr of borrowings against ₹106 Cr of equity in FY25, so its debt is 0.00× its equity. Over 5 years borrowings went from ₹2.0 Cr to ₹0.0 Cr. Over the last 3 of those years it spent ₹19.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

The spending on assets is being paid for from cash, not new debt.

No group of Prevest Denpro Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.1 points over the same period, to 0.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: +0.3 points over 8 quarters, to 0.7%; Domestic institutions: +0.1 points over 8 quarters, to 0.8%; Promoters: +0.0 points over 8 quarters, to 73.6%.

For Prevest Denpro Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

64.4 out of 100, rank 5 of 6 in Medical Equipment, with 43% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Prevest Denpro Ltd scores 64.4 out of 100 against the 6 companies it is compared with in Medical Equipment, ranking 5. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 23.5 + 23.6 + 17.3 = 64.4 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Prevest Denpro ranks 5 of 6 Medical Equipment companies on the 4-Factor Sector Score, with 64.4 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Medical Equipment, all 6 compared on one page.

Prevest Denpro is the 6th largest of 6 Medical Equipment companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Poly Medicure, Tarsons Products, Laxmi Dental, Hemant Surgical Industries and Vasa Denticity. It is the smallest.

Medical Equipment companies close in size

1. Poly Medicure Ltd ₹14,692 crore
2. Tarsons Products Ltd ₹1,548 crore
3. Laxmi Dental Ltd ₹977 crore
4. Hemant Surgical Industries Ltd ₹916 crore
5. Vasa Denticity Ltd ₹754 crore
6. Prevest Denpro Ltd ₹510 crore

All 6 Medical Equipment companies, largest first

Companies close in size in other industries

2118. Pansari Developers Ltd ₹454 crore · Construction - Housing
2119. Focus Lighting & Fixtures Ltd ₹452 crore · Capital Goods - Electric General
2120. Prevest Denpro Ltd ₹452 crore
2121. Modi Naturals Ltd ₹451 crore · Edible Oils, Agro Processing
2122. Mcleod Russel India Ltd ₹450 crore · Tea

Sector Alpha, written by code from the published numbers. Data as of 30 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.